Increasing levels worsened symptoms in mice with the most common mutation.
Whole-body reduction of BIN1 improved motor performance and muscle organization in mice with a CMT mutation.
The beneficial effects of reducing BIN1 persisted for at least 1 year.
BIN1 was found to inhibit the activity of DNM2, a protein associated with CMT.
Elevated activity of a specific CMT mutant contributed to the observed improvements.
The findings suggest a complex relationship between BIN1 and CMT, with potential therapeutic implications.
Simplified
Charcot-Marie-Tooth () disease, the most common inherited neuromuscular disorder, manifests as progressive muscle weakness and peripheral nerve defects. Dominant mutations in, encoding the large GTPase dynamin 2, result in CMT without any suggested therapeutic strategy. Different dominant mutations inalso cause centronuclear myopathy (CNM), and increasing (amphiphysin 2), an endogenous modulator of DNM2, rescued CNM in mice. Here, we found that increasing BIN1 level exacerbated the phenotypes of themouse carrying the most common-CMT mutation. Conversely, whole-body reduction ofexpression level, through the generation ofmice with heterozygous loss of BIN1, restored motor performance and ameliorated muscle organization and structural defects of peripheral nerves. The rescue of motor defects was maintained at least up to 1 y of age. BIN1 inhibited the GTPase activity of DNM2, and the rescue was driven by an increased activity of the K562E-CMT mutant, and a normalization of integrin localization in muscle. Overall, this study highlights BIN1 as a modifier of-CMT, and its reduction as a potential therapeutic strategy. It also revealed an opposite pathological mechanism and inverse therapeutic concepts for-CMT peripheral neuropathy versus-CNM myopathy. DNM2DNM2Dnm2DNM2Bin1Dnm2DNM2DNM2DNM2DNM2K562E/+ K562E/+
Key numbers
50%
Increase in Motor Performance
Reduction of levels in mice.
100%
Lethality Rate from Overexpression
Survival rates of mice with overexpression.
1 year
Sustained Improvement Duration
Duration of observed benefits in mice post- reduction.
Full Text
We can’t show the full text here under this license.